The S&P/ASX 200 Index has had an impressive start to the week and is notably higher in early afternoon trade. At the time of writing the benchmark index is up 0.55% to 6,214.7 points.
Four shares climbing more than most today are listed below. Here's why they have started the week on a high:
The Atomos Ltd (ASX: AMS) share price has surged 4% higher to $1.06 after the video technology company announced the expansion of its product range with the launch of three new products targeted at the rapidly growing social, pro-video, and entertainment segments of the video market. In addition to this, Atomos announced that it has collaborated with Dolby Vision to form a license agreement focused on meeting the needs of the entertainment industry.
The Avita Medical Ltd (ASX: AVH) share price has stormed 15% higher to 37.5 cents. This morning the global regenerative medicine company announced that interim results describing clinical outcomes for paediatric patients treated using its RECELL System were presented at the American Burn Association Annual Meeting in Las Vegas. This presentation appears to have caught the eye of investors.
The Resolute Mining Limited (ASX: RSG) share price has raced 8% higher to $1.26 following the release of a strong third quarter production update this morning. According to the release, the gold miner achieved total quarterly gold production of 98,105 ounces. This was up 47% on the prior corresponding period and 33% on the December quarter. Management advised the strong quarter was driven by the high grade and above budget recoveries achieved from its new mine at Tabakoroni and solid production at its Syama operation.
The Volpara Health Technologies Ltd (ASX: VHT) share price has rocketed 18% higher to $1.71 after the healthcare technology company announced that it has beaten its FY 2019 guidance. The company finished the financial year with Annual Recurring Revenue (ARR) of NZ$6.63 million, representing year on year growth of 86%. In addition to this, management advised that Volpara's software now covers 7.1% of all women screened in the United States. Volpara was targeting 85% ARR growth and a market share of 7%.
